Ascendis Pharma AS (ASND)
125.61
+0.33
(+0.26%)
USD |
NASDAQ |
Nov 04, 16:00
125.66
+0.06
(+0.04%)
After-Hours: 20:00
Ascendis Pharma Shareholders Equity (Quarterly): -344.22M for June 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -344.22M |
| March 31, 2024 | -257.21M |
| December 31, 2023 | -161.05M |
| September 30, 2023 | -77.73M |
| June 30, 2023 | 70.47M |
| March 31, 2023 | 182.32M |
| December 31, 2022 | 282.41M |
| September 30, 2022 | 443.83M |
| June 30, 2022 | 634.95M |
| March 31, 2022 | 750.94M |
| December 31, 2021 | 1.000B |
| September 30, 2021 | 1.152B |
| June 30, 2021 | 818.13M |
| March 31, 2021 | 941.14M |
| December 31, 2020 | 1.032B |
| September 30, 2020 | 1.117B |
| June 30, 2020 | 536.63M |
| March 31, 2020 | 605.33M |
| December 31, 2019 | 668.87M |
| September 30, 2019 | 723.12M |
| June 30, 2019 | 767.56M |
| Date | Value |
|---|---|
| March 31, 2019 | 804.81M |
| December 31, 2018 | 320.35M |
| September 30, 2018 | 353.49M |
| June 30, 2018 | 384.12M |
| March 31, 2018 | 428.33M |
| December 31, 2017 | 224.60M |
| September 30, 2017 | 238.15M |
| June 30, 2017 | 144.67M |
| March 31, 2017 | 165.45M |
| December 31, 2016 | 186.71M |
| September 30, 2016 | 83.47M |
| June 30, 2016 | 101.12M |
| March 31, 2016 | 115.50M |
| December 31, 2015 | 131.56M |
| September 30, 2015 | 148.21M |
| June 30, 2015 | 152.23M |
| March 31, 2015 | 161.56M |
| December 31, 2014 | 55.71M |
| September 30, 2014 | 3.171M |
| December 31, 2013 | 8.701M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-344.22M
Minimum
Jun 2024
1.152B
Maximum
Sep 2021
494.55M
Average
605.33M
Median
Mar 2020
Shareholders Equity (Quarterly) Benchmarks
| Evaxion Biotech AS | 0.074M |
| Adaptimmune Therapeutics PLC | 96.27M |
| Biodexa Pharmaceuticals PLC | 11.04M |
| NuCana PLC | 4.806M |
| Genfit SA | 75.11M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 812.82M |
| Total Liabilities (Quarterly) | 1.157B |
| Debt to Equity Ratio | -2.095 |
| Current Ratio | 0.74 |
| Net Debt Paydown Yield | -0.43% |